Aadi Bioscience, Inc. Overview
Pro stress-test →Aadi Bioscience is a commercial-stage biopharmaceutical company developing therapies for difficult-to-treat diseases, with a primary focus on bringing transformational therapies to cancer patients with mTOR pathway driver alterations. In March 2025, Aadi Bioscience was acquired by Japan-based KAKEN Pharmaceutical Co., Ltd.
Strategic Profile
Pro stress-test →As a commercial-stage precision oncology company, Aadi has received FDA approval and commercialized FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). Aadi's initial focus is the treatment of advanced malignant PEComa, an ultra-rare cancer, where it deployed its nab-particle technology to address unmet therapeutic needs in a highly specialized oncology segment.
Competitive Landscape
Pro stress-test →Aadi operates in the ultra-rare cancer and precision oncology space where direct competitors for mTOR-targeted therapies include specialized pharma players. The nab-particle formulation technology differentiates FYARRO from conventional mTOR inhibitors. Post-acquisition integration under KAKEN provides access to broader oncology pipelines and Japanese market distribution. Competitive positioning depends on FYARRO's real-world adoption and the expansion to additional mTOR-driven indications.
Industry Context
Aadi Bioscience, Inc. operates in Precision oncology therapeutics.
Key facts
Founded: 2011 · Headquarters: San Diego, US